|
US 11,299,552
|
Chimeric antigen receptor compositions and methods for use. Also, nucleic acid molecules and expression vectors for making and using the chimeric antigen receptors and for co-receptor signaling using such chimeric antigen receptors, and methods of treatment using such compositions. The chimeric antigen receptors interact with the endogenous T cell receptor complex enabling physiological control of signaling and T cell response and can be combined with ligands such as co-stimulatory ligands for further controlling and influencing T cell activation and response.
|
University of Kansas (Lawrence, KS, USA)
|
Yankee T, Szarejko J
|
4/12/2022
|
|
US 11,299,546
|
A chimeric antigen receptor comprising an antigen-binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Also, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs, and methods of detecting the presence of a proliferative disorder, for example, cancer, in a mammal and methods of treating or preventing a proliferative disorder, for example, cancer, in a mammal.
|
Secretary, US Department of Health and Human Services (Bethesda, MD, USA)
|
Chien CD, Fry TJ
|
4/12/2022
|
|
US 11,299,536
|
Compositions and methods for generating genetically modified T cells comprising a chimeric antigen receptor having an antigen-binding domain, a transmembrane domain, a costimulatory signaling region and a CD3ζ signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
|
The Trustees of the University of Pennsylvania (Philadelphia, PA, USA)
|
Frigault MJ, Zhao Y, Scholler J, June CH
|
4/12/2022
|
|
US 11,299,529
|
A chimeric antigen receptor comprising an extracellular spacer that comprises at least part of the extracellular domain of human low-affinity nerve growth factor (LNGFR) or a derivative thereof.
|
AGC Biologics (Bresso, Italy)
|
Bondanza A, Casucci M, Bonini MC
|
4/12/2022
|
|
US 11,299,525
|
A chimeric antigen receptor–modified immune effector cell carrying a programmed death-ligand 1 (PD-L1) blocking agent. Also, a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the antitumor effect of the chimeric antigen receptor–modified immune effector cell.
|
CRAGE Medical Co. Ltd. (Kowloon, Hong Kong)
|
Li Z, Pan Z, Shi Z, Song B, Wang P
|
4/12/2022
|
|
US 11,298,378
|
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor construct on the cell surface; materials and methods for genome editing to modulate the expression, function or activity of one or more immuno-oncology-related genes in a cell; and materials and methods for treating a patient using the genome-edited engineered cells.
|
CRISPR Therapeutics (Zug, Switzerland)
|
Terrett JA, Kalaitzidis D, Klein L
|
4/12/2022
|
|
US 11,286,306
|
Chimeric antigen receptor polypeptides that can be used with adoptive cell transfer to target and kill cancer cells that express TLR9 on their surface. Also, immune effector cells, such as T cells or natural killer (NK) cells that are engineered to express these CARs, and methods of providing an antitumor immunity in a subject with a TLR9-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
|
H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL, USA)
|
Abate-Daga; D, List AF, Wei S
|
3/29/2022
|
|
US 11,286,291
|
Novel co-stimulatory domains useful in genetically modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition. For example, genetically modified cells comprising a chimeric antigen receptor or an inducible regulatory construct incorporating the co-stimulatory domains. Also, plasmids and viral vectors comprising a nucleic acid sequence encoding the co-stimulatory domains, and methods of administering compositions comprising the novel co-stimulatory domains to subjects to reduce the symptoms, progression or occurrence of disease, such as cancer.
|
Precision BioSciences (Durham, NC, USA)
|
Jantz D, Martin A, Sunman J, MacLeod DT
|
3/29/2022
|
